A Case of Hepatic Tuberculosis in a Patient on Adalimumab for Ankylosing Spondylitis
Shayan Amini, Ronan Allencherril, Michelle Lin, Suzanne M Crumley, David W Victor
TL;DR
This paper reports a rare case of liver tuberculosis in a patient taking adalimumab for ankylosing spondylitis.
Contribution
The novelty lies in documenting hepatic TB in a patient on adalimumab, highlighting risks in immunosuppressed individuals.
Findings
Hepatic TB is uncommon and often secondary to other TB sources.
Immunosuppressive therapy, like adalimumab, increases the risk of TB.
This case emphasizes the need for TB screening in patients on immunosuppressants.
Abstract
Hepatic tuberculosis (TB) is an uncommon extrapulmonary manifestation of tuberculosis. Hepatic TB is more common in immunocompromised patients, such as those on immunosuppressive medications or those with a human immunodeficiency virus (HIV) infection. Primary hepatic TB is rare, and liver involvement is often secondary to spreading from the lymphatics, portal vein, or hepatic artery. We report a case of hepatic TB in a patient on adalimumab for ankylosing spondylitis (AS).
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiagnosis and treatment of tuberculosis · Tuberculosis Research and Epidemiology · Infectious Diseases and Tuberculosis